- Drug platform company Annovis Bio, Inc. ( NYSE: ANVS ) announced Tuesday the publication of three granted U.S. patents covering lead product candidate buntanetap.
- The patents relate to methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases with the treatment of buntanetap.
- "These additional patents represent further proof for our platform drug, buntanetap, which acts on a variety of neurodegenerative disorders by inhibiting multiple neurotoxic proteins," Chief Executive Maria L. Maccecchini remarked.
- The patents protect intellectual property rights through 2031 before consideration of any patent extensions.
- Ahead of the announcement, ANVS shares surged in the pre-market trading following a ~30% gain on Monday.
- Over the past six months, ANVS has added ~60%, outperforming the broader market, as shown in this graph.
For further details see:
Annovis Bio announces publication of three U.S. patents covering lead asset